ArticleVaccine2007
Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus.
Article in Vaccine, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 61 citations in OpenAlex.
- Research advances in replication-deficient viral vector vaccines.Frontiers in veterinary science · 2025Review
- RNA-Based Vaccines and Therapeutics Against Intracellular Pathogens.Methods in molecular biology (Clifton, N.J.) · 2024Review
- AnScience translational medicine · 2020Article
- Polysaccharide-based chromatographic adsorbents for virus purification and viral clearance.Journal of pharmaceutical analysis · 2020Review
- Development of novel vaccines against human cytomegalovirus.Human vaccines & immunotherapeutics · 2019Review
- Human cytomegalovirus vaccine development: Immune responses to look into vaccine strategy.Human vaccines & immunotherapeutics · 2018Article
- Progress toward Development of a Vaccine against Congenital Cytomegalovirus Infection.Clinical and vaccine immunology : CVI · 2017Review
- Production of Cytomegalovirus Dense Bodies by Scalable Bioprocess Methods Maintains Immunogenicity and Improves Neutralizing Antibody Titers.Journal of virology · 2016Article
- Cytomegalovirus vaccines under clinical development.Journal of virus eradication · 2016Article
- The immunological underpinnings of vaccinations to prevent cytomegalovirus disease.Cellular & molecular immunology · 2015Review
- Combination of alphavirus replicon particle-based vaccination with immunomodulatory antibodies: therapeutic activity in the B16 melanoma mouse model and immune correlates.Cancer immunology research · 2014Article
- Enhancement of antitumor immunity using a DNA-based replicon vaccine derived from Semliki Forest virus.PloS one · 2014Article
- Cytomegalovirus vaccines.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2013Review
- Cytomegalovirus vaccine strain towne-derived dense bodies induce broad cellular immune responses and neutralizing antibodies that prevent infection of fibroblasts and epithelial cells.Journal of virology · 2013Article
- Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus.Journal of virology · 2013Article
- Lack of interference with immunogenicity of a chimeric alphavirus replicon particle-based influenza vaccine by preexisting antivector immunity.Clinical and vaccine immunology : CVI · 2012Article
- Article
- Management of cytomegalovirus infection in solid organ transplantation.Nature reviews. Nephrology · 2010Review
- Update on the current status of cytomegalovirus vaccines.Expert review of vaccines · 2010Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
We used a replication-incompetent, single-cycle, alphavirus replicon vector system to produce virus-like replicon particles (VRP) expressing the extracellular domain of human cytomegalovirus (CMV) glycoprotein B or a pp65/IE1 fusion protein. Efficient production methods were scaled to produce pilot lots and clinical lots of each alphavirus replicon vaccine component. The vaccine induced high-titered antibody responses in mice and rabbits, as measured by ELISA and CMV neutralization assays, and robust T-cell responses in mice, as measured by IFN-gamma ELISPOT assay. A toxicity study in rabbits showed no adverse effects in any toxicology parameter. These studies support clinical testing of this novel CMV alphavirus replicon vaccine in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.